先健科技(01302.HK):深圳云麻与深圳先进院就工业大麻业务设立联合实验室
格隆汇9月17日丨先健科技(01302.HK)宣布,于2019年9月16日,公司透过深圳云麻与中国科学院深圳先进技术研究院达成联合实验室合作协议。根据合作协议,深圳云麻与中国科学院深圳先进技术研究院脑认知与脑疾病研究所共同合作成立了中国科学院深圳先进技术研究院-深圳市云麻生物科技有限公司联合实验室,加速开展大麻素干预脑疾病作用的相关科研工作,重点布局水溶性CBD在癫痫病、自闭症、恐惧症、帕金森病、睡眠障碍症等认知障碍性疾病的相关科学研究,并为未来的商业化安排积累数据。同时,双方将依托各自优势共同为联合实验室申请各级政府的科技资助项目。
目前,全球对于大麻素(含CBD)产品的相关科学研究及临床实践初步显示了其广泛的商业应用价值,是次联合实验室的成立将裨益于深圳云麻尽快推进大麻素在相关领域的应用研究。截止2019年9月17日,脑认知与脑疾病研究所已经成功培育脑神经疾病的基因突变动物模型,各方已经按确定的细节性试验方案开展相关研究。第一阶段重点开展水溶性CBD改善成年小鼠自闭症模型的社交行为、刻板样行为及睡眠障碍的研究;第二阶段重点开展水溶性CBD干预幼年自闭症的临床前研究及治疗帕金森病的探索性研究。相关实验数据将有助于推动Scintilla Health, Inc.(公司与索伦托药业共同成立的美国合资公司)就CBD药品在FDA的上市许可进程。
截止2019年9月17日,公司与索伦托药业已经就水溶性技术在CBD的应用领域取得相关研发进展,成功在大鼠动物模型上验证双方合作开发的水溶性产品相比脂溶性CBD药物有约4倍的生物利用度效果,同时可以更快达到血液峰值。该结果初步证明水溶性技术在医用、食用及消费品领域应用的技术优势,双方共同成立的合资公司将按照业务布局在相关领域进一步拓展业务。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.